Moreover, they have demonstrated a reduction in ligand-induced phosphorylation of EGFR and ErbB2 after the apigenin treatment, which plays a critical role in HNSCC development and progression [147]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.